

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope, with sufficient postage, addressed to: Commissioner for Patents, Washington, D.C. 20231, on

4/24/02

Date of Deposit

Gregory M. Zinkl, Ph.D.

Name of Applicant, Assignee or
Registered Representative

Signature

4/23/02

Date of Signature

RECEIVED
MAY 03 2002
5/15/02
H5
LNU
TECH CENTER 1600/2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Ashkenazi et al.

Serial No.: 09/944,884

Filing Date: August 31, 2001

For: SECRETED AND
TRANSMEMBRANE
POLYPEPTIDES AND NUCLEIC
ACIDS ENCODING THE SAME

Examiner: To be assigned

Group Art Unit No.: 1645

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

In compliance with the duty of disclosure under 37 C.F.R. § 1.56, it is respectfully requested that this Information Disclosure Statement be entered and the documents listed below and on the attached Form PTO-1449 be considered by the Examiner and

made of record. Copies of the listed documents required by 37 C.F.R. § 1.98(a)(2) are enclosed for the convenience of the Examiner.

The references now cited are the following:

OTHER ART

1. Blast Results A1-A11, GenBank
2. Blast Results, B1-B2, Dayhoff

In accordance with 37 C.F.R. § 1.97(g),(h), this Information Disclosure Statement is not to be construed as a representation that a search has been made and is not to be construed to be an admission that the information cited is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b).

This Information Disclosure Statement is being filed prior to the receipt of the first Official Action reflecting an examination on the merits and hence is believed to be timely filed in accordance with 37 C.F.R. § 1.97(b). No fees are believed to be due in connection with filing of this Information Disclosure Statement, however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary for any reason relating to these material, the Commissioner is hereby authorized to deduct said fees from Brinks Hofer Gilson & Lione Deposit Account No. 23-1925. A duplicate copy of this document is enclosed.


Applicant(s) respectfully request that the listed documents be made of record in the present case.

Respectfully submitted,



Gregory M. Zinkl, Ph.D.
Registration No. 48,492
Agent for Applicant(s)

BRINKS HOFER GILSON & LIONE
P.O. Box 10395
Chicago, IL 60610
(312) 321-4200



I hereby certify that this correspondence is being deposited with the United States Postal Service, with sufficient postage, as first class mail in an envelope addressed to:

Commissioner for Patents

Washington, D.C. 20231

on

4/24/02

Date of Deposit

Gregory M. Zinkl, Ph.D.

Name of applicant, assignee or
Registered Representative

gzmz

Signature

4/23/02

Date of Signature

RECEIVED
MAY 03 2002
TECH CENTER 1600/2900

Our Case No. 10466/134

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:)
Ashkenazi et al.)
Serial No. 09/944,884) Examiner To be assigned
Filing Date: August 31, 2001) Group Art Unit No. 1645
For SECRETED AND)
TRANSMEMBRANE)
POLYPEPTIDES AND NUCLEIC)
ACIDS ENCODING THE SAME)

RELEVANT PRIORITY DOCUMENTS

Commissioner for Patents
Washington, D.C. 20231


Dear Sir:

The following priority documents are relevant to the presently claimed invention:

1. 60/069334; filed 12/11/1997
2. PCT/US98/25108; filed 12/1/1998
3. 09/254311; filed 3/3/1999
4. PCT/US99/28301; filed 12/1/1999
5. PCT/US00/32678; filed 12/1/2000

6. 09/866028; filed 5/25/2001

Respectfully submitted,



Gregory M. Zinkl, Ph.D.
Registration No. 48,492
Agent for Applicant

BRINKS HOFER GILSON & LIONE
P.O. BOX 10395
CHICAGO, ILLINOIS 60610
(312) 321-4200